This database contains 457 studies, archived under the term: "drug therapy"
Click here to filter this large number of results.
Memantine for treatment of behavioural disturbances and psychotic symptoms in moderate to moderately severe Alzheimer dementia: a naturalistic study in outpatient services in Austria
Schmidt, Reinhold,
Baumhackl, Ulf,
Berek, Klaus,
Brücke, Thomas,
Kapeller, Peter,
Lechner, Anita,
Rainer, Michael,
Stögerer, Eva-Maria
We conducted an open, 16-week study on the efficacy of memantine on behavioral disturbances and psychotic symptoms in moderate to moderately severe Alzheimer s disease in daily routine. Fifty-three patients of 20 outpatient centers in Austria were recruited. The Neuropsychiatric Inventory (NPI) was defined as main outcome measure. After 16 weeks the total NPI score […]
Impact of a stepwise protocol for treating pain on pain intensity in nursing home patients with dementia: A cluster randomized trial
Sandvik, R. K.,
Selbaek, G.,
Seifert, R.,
Aarsland, D.,
Ballard, C.,
Corbett, A.,
Husebo, B. S.
Background: Pain is frequent and distressing in people with dementia, but no randomized controlled trials have evaluated the effect of analgesic treatment on pain intensity as a key outcome. Methods: Three hundred fifty‐two people with dementia and significant agitation from 60 nursing home units were included in this study. These units, representing 18 nursing homes […]
Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer’s disease
Salloway, Stephen,
Sperling, Reisa,
Fox, Nick C.,
Blennow, Kaj,
Klunk, William,
Raskind, Murray,
Sabbagh, Marwan,
Honig, Lawrence S.,
Porsteinsson, Anton P.,
Ferris, Steven,
Reichert, Marcel,
Ketter, Nzeera,
Nejadnik, Bijan,
Guenzler, Volkmar,
Miloslavsky, Maja,
Wang, Daniel,
Lu, Yuan,
Lull, Julia,
Tudor, Iulia Cristina,
Liu, Enchi,
Grundman, Michael,
Yuen, Eric,
Black, Ronald,
Brashear, H. Robert
Background: Bapineuzumab, a humanized anti-amyloid-beta monoclonal antibody, is in clinical development for the treatment of Alzheimer’s disease.; Methods: We conducted two double-blind, randomized, placebo-controlled, phase 3 trials involving patients with mild-to-moderate Alzheimer’s disease–one involving 1121 carriers of the apolipoprotein E (APOE) ε4 allele and the other involving 1331 noncarriers. Bapineuzumab or placebo, with doses varying […]
Effects of cilostazol on cognition and regional cerebral blood flow in patients with Alzheimer’s disease and cerebrovascular disease: a pilot study
Sakurai, Hirofumi,
Hanyu, Haruo,
Sato, Tomohiko,
Kume, Kazumasa,
Hirao, Kentaro,
Kanetaka, Hidekazu,
Iwamoto, Toshihiko
Aim: It remains unknown whether antiplatelet agents have a preventive effect on cognitive decline in patients with Alzheimer’s disease (AD). We investigated the effects of cilostazol, an antiplatelet agent and cyclic adenosine monophosphate phosphodiesterase 3 inhibitor, on cognition and regional cerebral blood flow (rCBF) in elderly patients with AD and cerebrovascular disease (CVD).; Methods: A […]
PF-04494700, an oral inhibitor of receptor for advanced glycation end products (RAGE), in Alzheimer disease
Sabbagh, Marwan N.,
Agro, Albert,
Bell, Joanne,
Aisen, Paul S,
Schweizer, Edward,
Galasko, Douglas
Objective: To evaluate the safety and tolerability of PF-04494700, an oral inhibitor of receptor for advanced glycation end products, in patients with mild-to-moderate dementia of the Alzheimer type.; Methods: Patients aged 50 years and older who met the National Institute of Neurological and Communicative Diseases and Stroke/Alzheimer’s Disease and Related Disorders Association criteria for Alzheimer […]
Evaluating the cognitive effects of donepezil 23 mg/d in moderate and severe Alzheimer’s disease: analysis of effects of baseline features on treatment response
Sabbagh, Marwan,
Cummings, Jeffrey,
Christensen, Daniel,
Doody, Rachelle,
Farlow, Martin,
Liu, Liang,
Mackell, Joan,
Fain, Randi
Background: Treatment of Alzheimer’s disease with acetylcholinesterase inhibitors can result in symptomatic benefits, but patients often show variable responses. The objective of this post hoc analysis was to investigate relationships between easily identifiable baseline characteristics/demographics and cognitive response in patients treated with either donepezil 23 mg/d or 10 mg/d and to identify factors potentially influencing response.; Methods: […]
Safety and efficacy of methylphenidate for apathy in Alzheimer’s disease: A randomized, placebo-controlled trial
Rosenberg, Paul B.,
Lanctôt, Krista L.,
Drye, Lea T.,
Herrmann, Nathan,
Scherer, Roberta W.,
Bachman, David L.,
Mintzer, Jacobo E.
Objective: In a recent crossover trial, methylphenidate treatment decreased apathy in Alzheimer’s disease. We further assessed this finding in the Apathy in Dementia Methylphenidate Trial (ADMET). Method: Six-week, randomized, double-blind, placebo-controlled multicenter trial enrolling Alzheimer’s disease participants (NINCDS-ADRDA criteria) with apathy assigned to methylphenidate 20 mg daily or placebo, conducted from June 2010 to December […]